{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bashir Q"],"funding":["NCI NIH HHS"],"pagination":["51-56"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9126091"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["57(1)"],"pubmed_abstract":["Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is an aggressive hematological malignancy; however, some patients achieve durable remission with allogeneic hematopoietic cell transplantation (allo-HCT). We report on all 17 patients with BPDCN who underwent allo-HCT at our center between 2000 and 2020. The median age was 39 (18-67) years. All (n = 16, 94%), except one patient, had systemic disease involving bone marrow and/or other organs. Ten patients (59%) were in first complete remission (CR1) at allo-HCT. The donor source was matched related or unrelated in ten (59%) and alternate donor in seven (41%) patients. Five (31%) patients developed acute graft-versus-host disease (GVHD), all grade I-II. The cumulative incidence (CI) of chronic GVHD at five-year was 34%. The CI of non-relap"],"journal":["Bone marrow transplantation"],"pubmed_title":["Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)."],"pmcid":["PMC9126091"],"funding_grant_id":["P30 CA016672"],"pubmed_authors":["Qazilbash MH","Ahmed S","Konopleva MY","Popat UR","Kebriaei P","Nieto Y","Rondon G","Al-Atrash G","Oran B","Shpall EJ","Pemmaraju N","Srour SA","Rezvani K","Milton DR","Hosing C","Khouri IF","Bashir Q","Saini NY","Olson AL","Champlin RE"],"additional_accession":[]},"is_claimable":false,"name":"Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).","description":"Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is an aggressive hematological malignancy; however, some patients achieve durable remission with allogeneic hematopoietic cell transplantation (allo-HCT). We report on all 17 patients with BPDCN who underwent allo-HCT at our center between 2000 and 2020. The median age was 39 (18-67) years. All (n = 16, 94%), except one patient, had systemic disease involving bone marrow and/or other organs. Ten patients (59%) were in first complete remission (CR1) at allo-HCT. The donor source was matched related or unrelated in ten (59%) and alternate donor in seven (41%) patients. Five (31%) patients developed acute graft-versus-host disease (GVHD), all grade I-II. The cumulative incidence (CI) of chronic GVHD at five-year was 34%. The CI of non-relap","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-04T19:31:35.245Z","creation":"2025-02-19T02:57:23.89Z"},"accession":"S-EPMC9126091","cross_references":{"pubmed":["34629467"],"doi":["10.1038/s41409-021-01478-5"]}}